Cansino Biologics Inc (688185)
Shanghai Stock Exchange · China · prices in CNY · close of 27 Oct 2026
Key indicators
| Last close | CNY 72.10 |
|---|---|
| 52-week range | 46.89 – 108.00 |
| Return, 1 month / 3 months | −11.7% / +46.4% |
| Return, 1 year / 3 years | −3.4% / −4.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 42 |
| Volatility (1 year) | 60.7% |
| Worst drawdown (1 year) | -39.5% |
| Average daily value traded | 652.31M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CanSino Biologics is a Chinese biopharmaceutical company based in Tianjin that researches, develops and manufactures vaccines. Its work centres on viral vector vaccine technology, and its products include vaccines against Ebola and respiratory infections such as the coronavirus. The company supplies public health authorities and immunization programmes, and it also provides contract research and manufacturing services for other vaccine developers. Its customers are mainly government health agencies and healthcare organisations in China and other countries.
On this site Cansino Biologics Inc appears as a stock on the Shanghai Stock Exchange (China), code 688185, with prices in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cansino Biologics Inc (688185) trades on the Shanghai Stock Exchange in China. It last closed at CNY 72.10 on 27 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 163 of 2,280 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.4% and over the last three months it rose 46.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 11.1% | ||
| From 52-week high | -29.8% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 46.4% | ||
| 6-month return | 9.5% | ||
| 12-month return, skipping the last month | 9.4% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 60.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.5% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 652.31M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −8.9% |
|---|---|
| 1 month | −11.7% |
| 3 months | +46.4% |
| 6 months | +9.5% |
| 1 year | −3.4% |
| 3 years | −4.7% |
| 5 years | −75.3% |
Signals
| 50-day / 200-day average | 74.58 / 64.88 |
|---|---|
| Golden / death cross (60 days) | Golden, 16 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.60 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Aug 2022 | CNY 0.8000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.